Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial

Martin Hutchings; Pieternella Lugtenburg; Rogier Mous; Michael Roost Clausen; Martine Chamuleau; Kim Linton; Simon Rule; Juanita Lopez; Roberto S. Oliveri; Dena DeMarco; Brian Elliott; Peter Johnson

Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial

Martin Hutchings
, Pieternella Lugtenburg
, Rogier Mous
, Michael Roost Clausen
, Martine Chamuleau
, Kim Linton
, Simon Rule
, Juanita Lopez
, Roberto S. Oliveri
, Dena DeMarco
, Brian Elliott
, Peter Johnson

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S274-S274
Number of pages	1
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Publication status	Published - Sept 2020

Keywords

antibody
B-cell lymphoma
BCL
immunotherapy
lymphoma

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hutchings, M., Lugtenburg, P., Mous, R., Clausen, M. R., Chamuleau, M., Linton, K., Rule, S., Lopez, J., Oliveri, R. S., DeMarco, D., Elliott, B., & Johnson, P. (2020). Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial. Clinical Lymphoma, Myeloma and Leukemia, 20, S274-S274.

@article{47074416e279450785516765476fe161,

title = "Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial",

keywords = "antibody, B-cell lymphoma, BCL, immunotherapy, lymphoma",

author = "Martin Hutchings and Pieternella Lugtenburg and Rogier Mous and Clausen, \{Michael Roost\} and Martine Chamuleau and Kim Linton and Simon Rule and Juanita Lopez and Oliveri, \{Roberto S.\} and Dena DeMarco and Brian Elliott and Peter Johnson",

year = "2020",

month = sep,

language = "English",

volume = "20",

pages = "S274--S274",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier BV",

}

Hutchings, M, Lugtenburg, P, Mous, R, Clausen, MR, Chamuleau, M, Linton, K, Rule, S, Lopez, J, Oliveri, RS, DeMarco, D, Elliott, B & Johnson, P 2020, 'Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial', Clinical Lymphoma, Myeloma and Leukemia, vol. 20, pp. S274-S274.

Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial. / Hutchings, Martin; Lugtenburg, Pieternella; Mous, Rogier et al.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, 09.2020, p. S274-S274.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial

AU - Hutchings, Martin

AU - Lugtenburg, Pieternella

AU - Mous, Rogier

AU - Clausen, Michael Roost

AU - Chamuleau, Martine

AU - Linton, Kim

AU - Rule, Simon

AU - Lopez, Juanita

AU - Oliveri, Roberto S.

AU - DeMarco, Dena

AU - Elliott, Brian

AU - Johnson, Peter

PY - 2020/9

Y1 - 2020/9

KW - antibody

KW - B-cell lymphoma

KW - BCL

KW - immunotherapy

KW - lymphoma

M3 - Meeting Abstract

SN - 2152-2650

VL - 20

SP - S274-S274

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -